Press Releases April 29, 2026 05:30 PM

INLIF LIMITED Regains Compliance with Nasdaq Bid Price Requirement

INLIF LIMITED Regains Compliance with Nasdaq Minimum Bid Price Requirement

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
INLF

INLIF LIMITED, listed on Nasdaq under ticker INLF, announced that it has regained compliance with Nasdaq's minimum bid price requirement after its stock price remained at or above $1.00 per share for 10 consecutive business days. This follows a previous notice from Nasdaq about the company's bid price falling below $1.00 for 30 consecutive business days. INLIF is engaged in R&D, manufacturing, and sales of injection molding machine-dedicated manipulator arms through its operating entity in China.

INLIF LIMITED Regains Compliance with Nasdaq Bid Price Requirement
INLF
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • INLIF has regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum bid price of $1.00 or above for 10 consecutive business days.
  • The company primarily operates in the manufacturing sector, focusing on injection molding machine-dedicated robotic manipulator arms, impacting industrial automation and manufacturing technology sectors.
  • The compliance helps preserve the stock's listing on the Nasdaq Capital Market, maintaining investor confidence and trading accessibility.

QUANZHOU, China, April 29, 2026 (GLOBE NEWSWIRE) -- INLIF LIMITED (NASDAQ: INLF) (together with all its subsidiaries and consolidated entities, the “Company” or “INLIF”), a company engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms, today announced that the Company has received a letter (the “Compliance Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).

As previously disclosed, on October 27, 2025, the Company received a notification letter from Nasdaq indicating that the closing bid price of the Company’s Class A ordinary shares had been below $1.00 per share for 30 consecutive business days. Nasdaq has since determined that, for the last 10 consecutive business days, from April 8, 2026 to April 21, 2026, the closing bid price of the Company’s Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

INLIF continues to be listed on The Nasdaq Capital Market under the ticker symbol “INLF”.

About INLIF LIMITED

INLIF is a holding company and an exempted company incorporated in the Cayman Islands with limited liability. Through its operating entity in the People's Republic of China, Ewatt Robot Equipment Co. Ltd., established in September 2016, INLIF is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. It is also a provider of installation services and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The Company produces an extensive portfolio of injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms, all developed by itself. For more information, please visit the Company’s website: https://ir.yiwate88.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the U.S. Securities and Exchange Commission (the "SEC"). Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov.

For investor and media inquiries, please contact:

INLIF LIMITED
Investor Relations Department
Email: ir@yiwate88.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com 


Risks

  • Stock prices remain volatile and could drop below the minimum bid price again, risking delisting and impacting shareholder value.
  • Risks related to market conditions and operational performance as outlined in the company's SEC filings could affect future financial results and stock performance.
  • Dependence on the manufacturing and industrial automation markets means economic downturns or reduced demand in these sectors could adversely impact the company's business and stock price.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026